Migraine
Recurrent moderate-to-severe headache, often with nausea and sensitivity to light or sound. Cannabis evidence is limited but observational and small-trial data suggest reduced headache frequency and acute-attack severity in some patients.
- 14 states
- QUALIFYING IN
- Limited
- EVIDENCE
- G43.909
- ICD-10
Reviewed by Laura H. Meyer
Qualifying states
What it is
Migraine is a recurrent neurological condition characterized by moderate-to-severe headache often unilateral, pulsating, and accompanied by nausea, vomiting, or sensitivity to light, sound, or smell. Some patients experience an aura (sensory or visual disturbance) preceding the headache. Chronic migraine is defined as 15 or more headache days per month for at least three months, with at least eight days meeting migraine criteria.
Cannabis and cannabis-derived therapies
Cannabis evidence for migraine is limited compared to the substantial evidence for chronic pain or chemotherapy-induced nausea. The 2017 NASEM consensus report did not identify high-tier evidence specific to migraine. Observational and survey data from medical-cannabis patients have reported reduced headache frequency, reduced acute-attack severity, and reduced use of opioid rescue medication.
Mechanisms commonly cited include cannabinoid modulation of CGRP, serotonergic and dopaminergic systems, and anti-nausea effects via 5-HT3 receptor activity. Trial-quality evidence remains sparse, and migraine-specific dosing protocols have not been established.
Practical considerations
Cannabis is typically used adjunctively with standard migraine therapies. Patients should coordinate cannabis use with their neurologist or headache specialist, particularly when also taking triptans, CGRP antagonists, or topiramate. Smoked cannabis is contraindicated when migraine is accompanied by significant photophobia or in environments where smoke would worsen symptoms. Oral or sublingual forms with longer onset are sometimes preferred for prevention; vaporization with faster onset is sometimes preferred for acute attacks.
Cannabis-overuse headache has been reported in some heavy users, paralleling the well-documented medication-overuse headache pattern with triptans or analgesics. Patients with chronic-migraine and high-frequency cannabis use should monitor for this pattern.
Important: patients with migraine should not substitute cannabis for prescribed migraine prophylaxis without coordinating with their physician. Untreated migraine reduces quality of life and can produce neurological complications.
Frequently asked questions
How strong is the cannabis evidence for migraine?
Limited but suggestive. The 2017 NASEM consensus report did not identify high-tier evidence for cannabis as a treatment for migraine. Subsequent observational studies and small open-label trials have reported reduced headache frequency and reduced acute-attack severity in some patients, but randomized controlled trials are sparse. Cannabis is most often used adjunctively alongside standard migraine therapies.
Is any cannabis-derived product FDA-approved for migraine?
No. No cannabis or cannabinoid product is FDA-approved for migraine in the United States. Standard migraine therapy uses triptans, CGRP-pathway monoclonal antibodies and gepants, topiramate, propranolol, and other preventive medications, plus acute-attack treatment with NSAIDs, triptans, or gepants.
Which migraine outcomes have the most cannabis-related evidence?
Headache frequency reduction and acute-attack severity reduction have the most patient-reported support in observational data. Sleep, nausea, and anxiety associated with migraine are also commonly cited. Cannabis-rebound or cannabis-induced headache has been reported in some heavy users; the relationship is dose-dependent and not fully characterized.
Which states qualify migraine for medical cannabis?
Several states explicitly enumerate migraine as a qualifying condition (including Illinois). Practitioner-discretion states (Oklahoma, New York post-2022, Missouri, Virginia post-2023) can certify for migraine within the discretion standard. States that recognize severe chronic pain often capture chronic migraine within that broader category.
Sources
- NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 16, 2026
- NIH NINDS: Migraineaccessed May 16, 2026